Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain (Q39267946)

10 September 2017

title

Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain (English)

1 reference

10 September 2017

0 references

Moreno

1

1 reference

10 September 2017

Clotet

2

1 reference

10 September 2017

Sarría

3

1 reference

10 September 2017

Ortega

4

1 reference

10 September 2017

Leal

5

1 reference

10 September 2017

Rodriguez-Arrondo

6

1 reference

10 September 2017

Sánchez-de la Rosa

7

1 reference

10 September 2017

Allegro Study Group

8

1 reference

10 September 2017

publication date

1 November 2009

1 reference

10 September 2017

1 reference

10 September 2017

volume

10

1 reference

10 September 2017

issue

6

1 reference

10 September 2017

page(s)

394-402

1 reference

Increased In Vitro Cytopathicity of CC Chemokine Receptor 5–Restricted Human Immunodeficiency Virus Type 1 Primary Isolates Correlates with a Progressive Clinical Course of Infection

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Novel targets for antiretroviral therapy: clinical progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Assessing chemokine co-receptor usage in HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

US FDA approves new class of HIV therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

CCR5 as target for HIV-1 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-394

21 January 2018

Identifiers

DOI

10.1310/HCT1006-394

1 reference

10 September 2017

1 reference